Annual report pursuant to Section 13 and 15(d)

Segment Disclosures

v3.23.1
Segment Disclosures
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment Disclosures Segment DisclosuresThe Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.
The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.

Segment reporting information is as follows:
EksoHealth EksoWorks Total
Year ended December 31, 2022
Revenue $ 11,830  $ 1,082  $ 12,912 
Cost of revenue 5,949  749  6,698 
Gross profit $ 5,881  $ 333  $ 6,214 
Year ended December 31, 2021
Revenue $ 9,750  $ 1,496  $ 11,246 
Cost of revenue 3,746  751  4,497 
Gross profit $ 6,004  $ 745  $ 6,749 


Geographically, the regions the Company operates in are the Americas, EMEA, and APAC. Individual countries with revenue greater than 10% of total revenue are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:
  Year ended December 31,
  2022 2021
United States $ 6,557 $ 6,451
Other 252  127 
Americas 6,809  6,578 
Germany 1,002  1,327 
Other 2,847  2,084 
EMEA 3,849  3,411 
APAC 2,254  1,257 
  $ 12,912  $ 11,246